BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38132150)

  • 1. Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma.
    Garcia N; Ulin M; Yang Q; Ali M; Bosland MC; Zeng W; Chen L; Al-Hendy A
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma.
    Shalaby S; Khater M; Laknaur A; Arbab A; Al-Hendy A
    Reprod Sci; 2020 Feb; 27(2):644-654. PubMed ID: 31925772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MR evaluation of uterine leiomyosarcoma and STUMP versus leiomyoma in symptomatic women planned for high frequency focussed ultrasound: accuracy of imaging parameters and interobserver agreement for identification of malignancy.
    Aminzadeh P; Alibrahim E; Dobrotwir A; Paul E; Goergen S
    Br J Radiol; 2021 Mar; 94(1119):20200483. PubMed ID: 33507806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
    Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
    Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presurgical Identification of Uterine Smooth Muscle Malignancies through the Characteristic FDG Uptake Pattern on PET Scans.
    Ho KC; Dean Fang YH; Lin G; Ueng SH; Wu TI; Lai CH; Chueh HY; Chao A; Chang TC; Yen TC
    Contrast Media Mol Imaging; 2018; 2018():7890241. PubMed ID: 30018513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
    Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine Leiomyosarcoma: Can MRI Differentiate Leiomyosarcoma From Benign Leiomyoma Before Treatment?
    DeMulder D; Ascher SM
    AJR Am J Roentgenol; 2018 Dec; 211(6):1405-1415. PubMed ID: 30354268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma?
    Exacoustos C; Romanini ME; Amadio A; Amoroso C; Szabolcs B; Zupi E; Arduini D
    J Clin Ultrasound; 2007 Oct; 35(8):449-57. PubMed ID: 17636502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging.
    Sun S; Bonaffini PA; Nougaret S; Fournier L; Dohan A; Chong J; Smith J; Addley H; Reinhold C
    Diagn Interv Imaging; 2019 Oct; 100(10):619-634. PubMed ID: 31427216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
    Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
    Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine smooth muscle tumours with hyperintense area on T
    Ando T; Kato H; Furui T; Morishige KI; Goshima S; Matsuo M
    Br J Radiol; 2018 Apr; 91(1084):20170767. PubMed ID: 29308922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case of uterine leiomyoma showing fludeoxyglucose uptake on F-18 fludeoxyglucose positron emission tomography/computed tomography.
    Park JH; Han JY; Hyun IY; Lee BI; Moon YS
    J Obstet Gynaecol Res; 2010 Dec; 36(6):1261-4. PubMed ID: 21083837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
    Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
    Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of dystrophin is common in uterine leiomyosarcoma: a potential biomarker for clinical application.
    Vadasz B; Felicelli C; Feng Y; Yin P; Zhang Q; Bulun S; Wei JJ
    Hum Pathol; 2023 Apr; 134():85-91. PubMed ID: 36549601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI.
    Kusunoki S; Terao Y; Ujihira T; Fujino K; Kaneda H; Kimura M; Ota T; Takeda S
    Taiwan J Obstet Gynecol; 2017 Aug; 56(4):508-513. PubMed ID: 28805609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
    Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
    Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative [
    Lee JW; Park JY; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1309-1316. PubMed ID: 29492644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR imaging findings of unusual leiomyoma and malignant uterine myometrial tumors: what the radiologist should know.
    Fujii S; Mukuda N; Ochiai R; Yunaga H; Murakami A; Gonda T; Kishimoto M; Yamaji D; Ishibashi M
    Jpn J Radiol; 2021 Jun; 39(6):527-539. PubMed ID: 33517507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.